tapebrief
CNC · Q2 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CNC · Q3 2025 Earnings

Centene Corporation

Reported October 29, 2025

30-second summary

Centene raised FY2025 adjusted EPS guidance by $0.25 to at least $2.00, with Q3 adjusted EPS of $0.50 (including ~$0.10 of timing-driven tax benefit per management) against a $13.50 GAAP loss driven by a $6.7B non-cash goodwill impairment. Ex-impairment, operating margin is roughly -0.4%, not the headline -14%. Medicaid HBR of 93.4% beat the 93.5% H2 guide, with management now tracking to ~93.2% back-half — a ~30bp beat. The FY raise is anchored in operating items: a Florida CMS retroactive revenue adjustment, slight SG&A outperformance, and stronger investment income, with the Q3 tax benefit a timing item that reverses (FY tax rate guide reaffirmed at 20–21%). The consolidated HBR of 92.7% is +350bps YoY, reflecting genuine cost pressure in Marketplace and PDP. The 2026 framing is conservatism on top of a beat, not a deferral.

Headline numbers

EPS

Q3 FY2025

$0.50

Revenue

Q3 FY2025

$49.69B

+18.2% YoY

Operating margin

Q3 FY2025

-14.0%

Key financials

Q3 FY2025
MetricQ3 FY2025YoY
Revenue$49.69B+18.2%
EPS$0.50—
Operating margin-14.0%—

Guidance

Adjusted EPS guidance for FY2025 raised $0.25 to at least $2.00, offsetting substantial Q3 operating losses and signaling confidence in margin recovery trajectory.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted Diluted EPS
FY2025
$1.75at least $2.00+$0.25 (14.3% increase)Raised

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Medicaid$23.171B+9.0%
Commercial$10.992B+26.0%
Medicare$9.391B+66.0%
Other$1.344B+8.0%
Medicaid HBR93.4%—
Commercial HBR89.9%—
Medicare HBR94.3%—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Health Benefits Ratio (HBR)92.7%
SG&A Expense Ratio7.0%
Total At-Risk Membership27,968,100
Days in Claims Payable48 days
Adjusted Effective Tax Rate2.5%

Management tone

Q1 (pre-coverage) → Q2 capitulation ($5.50 EPS cut, "disappointed," "unacceptable") → Q3 measured optimism on operating execution paired with explicit conservatism around policy-driven 2026 variables.

On Medicaid 2026, Sarah characterised "a prudent posture for 2026 [as] profitability consistent with our current full-year outlook in 2025," adding "I will be disappointed if that's all we can deliver. But we think that that is a prudent assumption at this time, given where we stand and what we know and also what we don't yet know." Critically, "consistent with 2025" now references the raised ≥$2.00 outlook and the ~93.2% back-half HBR trajectory, not the prior $1.75 / 93.5% framing — this is conservatism layered on top of a beat, not a deferral of recovery.

The marketplace narrative has flipped from growth-with-margin to margin-over-membership. Management is explicitly planning for a "high teens to mid-30s" market contraction in 2026 across scenarios, with repricing completed across 95% of membership in the mid-30s average. Centene is also building incremental reserves against marketplace volatility — "we are holding the remaining $125 million of this provision in Q4 and are adding another $75 million given the volatility around EAPTCs. While we may not need this cover, as of now we believe this to be a prudent posture given the landscape uncertainty that remains." This is contingency-building against policy risk, not loss of operating confidence.

Management has moved from deterministic planning to scenario-dependent planning on policy. Drew's "we may find ourselves with a special enrollment period or an extension" and "we are certainly prepared to do everything we can" replace last quarter's narrower repricing-led playbook. Enhanced APTC expiration, work requirements in 2027, and program integrity are now treated as binary risks management is positioning around rather than baselining through.

Recurring themes management leaned on this quarter:

Medicaid margin stabilization through rate advocacy and clinical interventionsMarketplace pricing discipline prioritizing profitability over membership growthPolicy uncertainty (EAPTCs, work requirements, program integrity) as primary risk vectorData-driven decision-making informed by weekly claims and state-level partnershipsMedicare Advantage progress toward breakeven in 2027 with near-term PDP margin pressureAdministrative expense leverage and operational efficiency execution

Risks management surfaced:

EAPTC expiration or Congressional changes to subsidies during open enrollmentWork requirements implementation in 2027 creating expansion population risk pool shiftMarketplace member breakage and adverse selection if mid-cycle policy changes occurContinued elevated medical cost trend in behavioral health, ABA, and high-cost drugs despite mitigation effortsState budget pressures in 2026-2027 limiting rate increases and forcing program design trade-offs

Answers to last quarter's watch list

Marketplace 2026 target margins — Not directly disclosed in the press release; management's qualitative posture has shifted to margin-over-membership with explicit planning for "high teens to mid-30s" market contraction in 2026. Rate filings averaging mid-30s across 95% of membership are positioned for "meaningful margin improvement" in 2026, but no quantified margin target.
Continue monitoring
Medicaid HBR trajectory toward the ~93.5% H2 guide — Q3 Medicaid HBR of 93.4% beat the guide; management is now tracking to ~93.2% back-half, a ~30bp beat. The downside scenario from last quarter ($1.25 FY EPS) is off the table; FY EPS raised to ≥$2.00.
Resolved positively
2026 marketplace membership disclosure — Management now characterises the 2026 market as contracting "high teens to mid-30s," consistent with the upper-middle of last quarter's 15–50% disenrollment band. No formal Centene-specific membership guide yet.
Continue monitoring
Share of health plans outperforming HBR targets — Not updated in this print.
Not resolved
Capital position and liquidity — Days in claims payable held at 48; debt-to-cap at 45.5% post-impairment versus a 60% covenant; $357M unregulated cash, $200M Q4 subsidiary dividends expected. Buyback cadence not addressed.
Continue monitoring

What to watch into next quarter

Q4 Medicaid HBR vs the ~93.2% back-half trajectory — whether Centene holds the beat or gives some back as the Florida retro benefit doesn't repeat

2026 initial EPS guide framing in February — whether management quantifies "meaningful margin improvement" in Marketplace and Medicare Advantage, and whether Medicaid 2026 anchors above the "consistent with 2025" floor Sarah flagged

Marketplace reserve release or build in Q4 — the $125M held plus $75M added totals $200M of EAPTC contingency. Whether this releases or extends into 2026 is a clean read on management's residual policy-risk view

PDP 2026 pre-tax margin guide — Drew signaled PDP would "come out of the gate something less than" the 2025 "in the threes" level (vs. original 1% 2025 guide), making this a year-over-year segment headwind despite still likely running above original framing

EAPTC policy resolution and open enrollment breakage — the binary policy outcome and Centene's ability to recapture members in an extension scenario will drive the 2026 membership outcome within the "high teens to mid-30s" contraction range

GAAP-to-adjusted bridge — a $13.50 GAAP loss against $0.50 adjusted EPS is dominated by the $13.69 per share goodwill impairment; the recurring adjustment run-rate is far smaller

Sources

  1. Centene Q3 FY2025 press release, October 29, 2025 (SEC filing)
  2. Centene Q3 FY2025 earnings call transcript, October 29, 2025

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.